Antineoplastic drugs in urban wastewater: Occurrence, nanofiltration treatment and toxicity screening*

Detalhes bibliográficos
Autor(a) principal: Gouveia, TIA
Data de Publicação: 2023
Outros Autores: Cristóvão, MB, Pereira, VJ, Crespo, JG, Alves, A, Ribeiro, AR, Silva, A, Santos, MSF
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://hdl.handle.net/10216/154323
Resumo: Antineoplastic drugs are pharmaceuticals that have been raising concerns among the scientific community due to: (i) their increasing prescription in the fight against the disease of the twentieth century (cancer); (ii) their recalcitrance to conventional wastewater treatments; (iii) their poor environmental biodegradability; and (iv) their potential risk to any eukaryotic organism. This emerges the urgency in finding solutions to mitigate the entrance and accumulation of these hazardous chemicals in the environment. Advanced oxidation processes (AOPs) have been taken into consideration to improve the degradation of antineoplastic drugs in wastewater treatment plants (WWTPs), but the formation of by-products that are more toxic or exhibit a different toxicity profile than the parent drug is frequently reported. This work evaluates the performance of a nanofiltration pilot unit, equipped with a Desal 5DK membrane, in the treatment of real WWTP effluents contaminated (without spiking) with eleven pharmaceuticals, five of which were never studied before. Average removals of 68 & PLUSMN; 23% were achieved for the eleven compounds, with decreasing risks from feed to permeate for aquatic organisms from receiving waterbodies (with the exception of cyclophosphamide, for which a high risk was estimated in the permeate). Aditionally, no significative impact on the growth and germination of three different seeds (Lepidium sativum, Sinapis alba, and Sorghum saccharatum) were determined for permeate matrix in comparison to the control.
id RCAP_77bc0901a2d4fa86fd2712a56939019b
oai_identifier_str oai:repositorio-aberto.up.pt:10216/154323
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Antineoplastic drugs in urban wastewater: Occurrence, nanofiltration treatment and toxicity screening*Urban wastewaterAnticancer drugsCytostatic drugsPilot-scale treatmentNanofiltrationToxicity screeningAntineoplastic drugs are pharmaceuticals that have been raising concerns among the scientific community due to: (i) their increasing prescription in the fight against the disease of the twentieth century (cancer); (ii) their recalcitrance to conventional wastewater treatments; (iii) their poor environmental biodegradability; and (iv) their potential risk to any eukaryotic organism. This emerges the urgency in finding solutions to mitigate the entrance and accumulation of these hazardous chemicals in the environment. Advanced oxidation processes (AOPs) have been taken into consideration to improve the degradation of antineoplastic drugs in wastewater treatment plants (WWTPs), but the formation of by-products that are more toxic or exhibit a different toxicity profile than the parent drug is frequently reported. This work evaluates the performance of a nanofiltration pilot unit, equipped with a Desal 5DK membrane, in the treatment of real WWTP effluents contaminated (without spiking) with eleven pharmaceuticals, five of which were never studied before. Average removals of 68 & PLUSMN; 23% were achieved for the eleven compounds, with decreasing risks from feed to permeate for aquatic organisms from receiving waterbodies (with the exception of cyclophosphamide, for which a high risk was estimated in the permeate). Aditionally, no significative impact on the growth and germination of three different seeds (Lepidium sativum, Sinapis alba, and Sorghum saccharatum) were determined for permeate matrix in comparison to the control.Elsevier20232023-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/10216/154323eng0269-74911873-642410.1016/j.envpol.2023.121944Gouveia, TIACristóvão, MBPereira, VJCrespo, JGAlves, ARibeiro, ARSilva, ASantos, MSFinfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-11-29T13:54:20Zoai:repositorio-aberto.up.pt:10216/154323Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T23:50:20.803118Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Antineoplastic drugs in urban wastewater: Occurrence, nanofiltration treatment and toxicity screening*
title Antineoplastic drugs in urban wastewater: Occurrence, nanofiltration treatment and toxicity screening*
spellingShingle Antineoplastic drugs in urban wastewater: Occurrence, nanofiltration treatment and toxicity screening*
Gouveia, TIA
Urban wastewater
Anticancer drugs
Cytostatic drugs
Pilot-scale treatment
Nanofiltration
Toxicity screening
title_short Antineoplastic drugs in urban wastewater: Occurrence, nanofiltration treatment and toxicity screening*
title_full Antineoplastic drugs in urban wastewater: Occurrence, nanofiltration treatment and toxicity screening*
title_fullStr Antineoplastic drugs in urban wastewater: Occurrence, nanofiltration treatment and toxicity screening*
title_full_unstemmed Antineoplastic drugs in urban wastewater: Occurrence, nanofiltration treatment and toxicity screening*
title_sort Antineoplastic drugs in urban wastewater: Occurrence, nanofiltration treatment and toxicity screening*
author Gouveia, TIA
author_facet Gouveia, TIA
Cristóvão, MB
Pereira, VJ
Crespo, JG
Alves, A
Ribeiro, AR
Silva, A
Santos, MSF
author_role author
author2 Cristóvão, MB
Pereira, VJ
Crespo, JG
Alves, A
Ribeiro, AR
Silva, A
Santos, MSF
author2_role author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Gouveia, TIA
Cristóvão, MB
Pereira, VJ
Crespo, JG
Alves, A
Ribeiro, AR
Silva, A
Santos, MSF
dc.subject.por.fl_str_mv Urban wastewater
Anticancer drugs
Cytostatic drugs
Pilot-scale treatment
Nanofiltration
Toxicity screening
topic Urban wastewater
Anticancer drugs
Cytostatic drugs
Pilot-scale treatment
Nanofiltration
Toxicity screening
description Antineoplastic drugs are pharmaceuticals that have been raising concerns among the scientific community due to: (i) their increasing prescription in the fight against the disease of the twentieth century (cancer); (ii) their recalcitrance to conventional wastewater treatments; (iii) their poor environmental biodegradability; and (iv) their potential risk to any eukaryotic organism. This emerges the urgency in finding solutions to mitigate the entrance and accumulation of these hazardous chemicals in the environment. Advanced oxidation processes (AOPs) have been taken into consideration to improve the degradation of antineoplastic drugs in wastewater treatment plants (WWTPs), but the formation of by-products that are more toxic or exhibit a different toxicity profile than the parent drug is frequently reported. This work evaluates the performance of a nanofiltration pilot unit, equipped with a Desal 5DK membrane, in the treatment of real WWTP effluents contaminated (without spiking) with eleven pharmaceuticals, five of which were never studied before. Average removals of 68 & PLUSMN; 23% were achieved for the eleven compounds, with decreasing risks from feed to permeate for aquatic organisms from receiving waterbodies (with the exception of cyclophosphamide, for which a high risk was estimated in the permeate). Aditionally, no significative impact on the growth and germination of three different seeds (Lepidium sativum, Sinapis alba, and Sorghum saccharatum) were determined for permeate matrix in comparison to the control.
publishDate 2023
dc.date.none.fl_str_mv 2023
2023-01-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://hdl.handle.net/10216/154323
url https://hdl.handle.net/10216/154323
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 0269-7491
1873-6424
10.1016/j.envpol.2023.121944
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799135822659715072